About Xenon Pharmaceuticals Inc. - Common Shares (XENE)
Xenon Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of innovative therapeutics for neurological disorders and other serious conditions. Utilizing its proprietary gene modulation platform, the company aims to identify and advance novel drug candidates that target the underlying causes of diseases rather than merely addressing symptoms. By leveraging its expertise in genetic insights and biochemical pathways, Xenon strives to improve patient outcomes through precision medicine, building a robust pipeline of potential treatments for conditions such as epilepsy and other central nervous system disorders. Read More
VANCOUVER, British Columbia and BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today reported financial results for the fourth quarter and full year ended December 31, 2025 and provided a business update.
VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to ten new non-officer employees consisting of an aggregate of 42,300 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of January 15, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
As the global economy shakes off the final remnants of the high-interest-rate era, a massive wave of consolidation is sweeping through corporate boardrooms. Analysts have officially adjusted their forecasts for 2026, projecting a staggering $5.1 trillion in total deal volume—a figure that would eclipse the previous records of
VANCOUVER, British Columbia and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today outlined forward momentum across the Company’s Phase 3 portfolio and discussed pipeline progress at the 2026 J.P. Morgan Healthcare Conference.
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine franchise by Pfizer Inc. (NYSE: PFE) in 2022, the "new" Biohaven—often called Biohaven 2.0—is grappling with the harsh realities of clinical-stage drug development. The [...]
VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12-15, 2026.
The opening days of 2026 have ushered in a definitive regime shift in the global financial markets, as the long-awaited "Great Rotation" finally takes hold. After years of dominance by a handful of mega-cap technology titans, investors are aggressively reallocating capital into the small-cap sector, propelling the Russell 2000 Index
VANCOUVER, British Columbia and BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced new data highlighting its commitment in epilepsy, including interim 48-month data from its ongoing X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures (FOS), multiple real world studies on the burden of depression and anti-seizure medication (ASM) titration in epilepsy, and new data for its pre-clinical program in Dravet syndrome. These data are being presented at the American Epilepsy Society Annual Meeting (AES 2025), taking place December 5-9, 2025 in Atlanta, Georgia.
VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to five new non-officer employees consisting of an aggregate of 39,250 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of December 4, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
